MD Anderson
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
MD Anderson, Summit Therapeutics to Jointly Study Ivonescimab
The partners inked a five-year deal to study the PD-1/VEGF bispecific antibody across multiple tumor types, including in biomarker-defined indications.
Although the PETRA trial didn't test saruparib against marketed PARP inhibitors, researchers see promising signs that the agent has a better toxicity profile.
Replay, MD Anderson Venture Syena Bets on NK Cells to Bring TCR Therapy to Solid, Blood Cancers
Premium
After launching the first therapy, NY-ESO-1 TCR/IL-15 NK, in a multiple myeloma trial earlier this month, Syena is exploring the approach in new targets and tumor types.
Syena Starts Cell Therapy Trial in NY-ESO-1-Positive Multiple Myeloma
The Replay and MD Anderson subsidiary has treated the first multiple myeloma patient with its cord blood-derived TCR-NK cell therapy in a Phase I/II trial.